Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Initial data anticipated in the first half of 2025. - - Phase 1 study of CX-801 (interferon alpha-2b PROBODY® cytokine) as ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...

Shares in Merck & Co (NYSE: MRK) were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant earlier announced its financial results for the third quarter of ...

the Akeso and Summit Therapeutics drug that bested Keytruda in a Phase 3 trial in lung cancer. Crescent’s drug, he claimed, is a “purpose-built molecule designed to recapitulate precisely the ...